Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted CBT in OCD
NCT05783817Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of midomafetamine in obsessive compulsive disorder (OCD) (2 arms). Primary endpoint: Yale-Brown Obsessive Compulsive Scale at 2 weeks. Started Sep 2025; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT05783817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783817.